ACAT2 and Hypercholesterolemia: Pyripyropenes, in particular pyripyropene A (4), were discovered as a highly potent selective inhibitor of the ACAT-2 isoform, which was considered a new therapeutic target for the treatment and prevention of hypercholesterolemia and atherosclerosis [14].